Cancer Research and Treatment

Special Article

Choosing Wisely: The Korean Perspective and Launch of the ‘Right Decision in Cancer Care’ Initiative: Joo-Young Kim, Kyoung Eun Lee, Kyubo Kim, Myung Ah Lee, Won Sup Yoon, Dong Seok Han, Sung Gwe Ahn, Jung-Hun Kang; Cancer Res Treat. 2020;52(3):655-660. Published online June 2, 2020; DOI: https://doi.org/10.4143/crt.2020.221

Government healthcare expenditure is rising in Korea, and the costs incurred by patients in Korea exceed those incurred by patients in other Organization for Economic Co-operation and Development countries. Despite the increasing health expenditure, patient demand for services is increasing as well, so it is now becoming recognized that cancer care needs to be balanced. The most important measure in cancer care optimization is to provide high-quality care while keeping costs sustainable. The Korean Cancer Association considers the current situation of cancer therapy in Korea the foremost issue, which has led to the implementation of the nationwide ‘Right Decisions in Cancer Care’ initiative. This initiative is based on the concepts of medical professionalism in that it should be led by physicians working in the field of oncology, that education should be offered to patients and clinicians, and that it should influence healthcare policy. In this article, we introduce the nationwide ‘Right Decision in Cancer Care’ initiative and highlight the five initial items on its agenda. The agenda is open to expansion and update as the medical environment evolves and additional clinical evidence becomes available.

Citations

Citations to this article as recorded by

Relationship between patient outcomes and patterns of fragmented cancer care in older adults with gastric cancer: A nationwide cohort study in South Korea
Dong-Woo Choi, Seungju Kim, Sun Jung Kim, Dong Wook Kim, Kwang Sun Ryu, Jae Ho Kim, Yoon-Jung Chang, Kyu-Tae Han
Journal of Geriatric Oncology.2024; 15(2): 101685. CrossRef
Pattern of practice for postoperative management of endometrial cancer in Korea: a survey by the Korean Gynecologic Oncology Group and the Korean Radiation Oncology Group (KGOG 2028-KROG 2104)
Sung Uk Lee, Joo-Young Kim, Min Kyu Kim, Young Seok Kim, Yeon Joo Kim, Keun-Yong Eom, Chan Woo Wee
Journal of Gynecologic Oncology.2023;[Epub] CrossRef
The Future of Adjuvant Therapy in Renal Cell Carcinoma: Recent Insights and Prospects
Hyerim Ha, Joo Han Lim
Journal of Urologic Oncology.2023; 21(3): 208. CrossRef
Validation of the Korean Version of the Patient-Reported Outcomes Measurement Information System 29 Profile V2.1 among Cancer Survivors
Danbee Kang, Youngha Kim, Jihyun Lim, Junghee Yoon, Sooyeon Kim, Eunjee Kang, Heesu Nam, Sungkeun Shim, Mangyeong Lee, Haesook Bok, Sang-Won Lee, Soo-Yong Shin, Jin Seok Ahn, Dongryul Oh, Juhee Cho
Cancer Research and Treatment.2022; 54(1): 10. CrossRef
Comparison of Cancer-Related Spending and Mortality Rates in the US vs 21 High-Income Countries
Ryan D. Chow, Elizabeth H. Bradley, Cary P. Gross
JAMA Health Forum.2022; 3(5): e221229. CrossRef

15,558 View
174 Download
4 Web of Science
5 Crossref

Original Articles

Chemotherapy versus Best Supportive Care in Advanced Biliary Tract Carcinoma: A Multi-institutional Propensity Score Matching Analysis: Jun Ho Ji, Young Saing Kim, Inkeun Park, Soon Il Lee, Rock Bum Kim, Joon Oh Park, Sung Yong Oh, In Gyu Hwang, Joung-Soon Jang, Haa-Na Song, Jung-Hun Kang; Cancer Res Treat. 2018;50(3):791-800. Published online August 23, 2017; DOI: https://doi.org/10.4143/crt.2017.044

Abstract PDF PubReader ePub

Purpose
Although chemotherapy is recommended by various guidelines for advanced biliary tract cancer (BTC), the evidence supporting its use over best supportive care (BSC) is limited. The aim of this study was to investigate the survival benefit of chemotherapy over that of BSC in advanced BTC patients.
Materials and Methods
Advanced BTC patientswith a good performance status (Eastern CooperativeOncologyGroup [ECOG] 0-2) were eligible for the study. Data were retrospectively collected from four tertiary cancer centers and analyzed using propensity score matching (PSM). Of the 604 patients enrolled, 206 received BSC and 398 received chemotherapy. PSM analysis was performed using the following variables: age, ECOG status, carcinoembryonic antigen (CEA) level, white blood cell level, albumin level, total bilirubin level, and aspartate aminotransferase level. The sample size of each group was 164 patients after PSM. Median survival was compared between the two groups by using the Kaplan-Meier method, and prognostic factors were investigated using Cox proportional regression analysis.
Results
In post-PSM analysis, the respective median survival for the chemotherapy and BSC groups was dependent on the following prognostic factors: total population, 12.0 months vs. 7.5 months (p=0.001); locally advanced disease, 16.7 months vs. 13.4 months (p=0.490); cancer antigen 19-9 ≤ 100 IU/mL, 12.7 months vs. 10.6 months (p=0.330); and CEA ≤ 3.4 ng/mL, 17.1 months vs. 10.6 months (p=0.052).
Conclusion
Chemotherapy improved overall survival of patients with advanced BTC who had a good performance status. However, this survival benefit was not observed in BTC patients with locally advanced disease or with lower tumor marker. Individualized approach is needed for initiation of palliative chemotherapy in advanced BTC.

Citations

Citations to this article as recorded by

National guidelines for the diagnosis and treatment of hilar cholangiocarcinoma
Faisal Saud Dar, Zaigham Abbas, Irfan Ahmed, Muhammad Atique, Usman Iqbal Aujla, Muhammad Azeemuddin, Zeba Aziz, Abu Bakar Hafeez Bhatti, Tariq Ali Bangash, Amna Subhan Butt, Osama Tariq Butt, Abdul Wahab Dogar, Javed Iqbal Farooqi, Faisal Hanif, Jahanzai
World Journal of Gastroenterology.2024; 30(9): 1018. CrossRef
Treatment patterns and survival in older adults with unresected nonmetastatic biliary tract cancers
Ali Belkouz, Elise de Savornin Lohman, Jyothi R. Thumma, Bas Groot Koerkamp, Philip R. de Reuver, Martijn G.H. van Oijen, Cornelis J.A. Punt, Hari Nathan, Heinz-Josef Klümpen
Journal of Geriatric Oncology.2023; 14(3): 101447. CrossRef
Main causes of death in advanced biliary tract cancer
Kana Kimura‐Seto, Yasushi Kojima, Shiori Komori, Yuya Hisada, Yuki Otake, Yuka Yanai, Akiko Saito, Naoki Akazawa, Yasuo Tanaka, Chizu Yokoi, Mikio Yanase, Junichi Akiyama, Natsuyo Yamamoto, Kazuhiko Yamada
Cancer Medicine.2023; 12(9): 10889. CrossRef
A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract Cancer
Vivian Peirce, Michael Paskow, Lei Qin, Ruby Dadzie, Maria Rapoport, Samantha Prince, Sukhvinder Johal
Targeted Oncology.2023; 18(6): 837. CrossRef
Short- and Long-Term Survival of Metastatic Biliary Tract Cancer in the United States From 2000 to 2018
Van Nghiem, Sarah Wood, Rekha Ramachandran, Grant Williams, Darryl Outlaw, Ravikumar Paluri, Young-il Kim, Olumide Gbolahan
Cancer Control.2023;[Epub] CrossRef
Anticancer Drugs Compared to No Anticancer Drugs in Patients with Advanced Hepatobiliary Cancer: A Mapping Review and Evidence Gap Map
Carolina Requeijo, Javier Bracchiglione, Nicolás Meza, Roberto Acosta-Dighero, Josefina Salazar, Marilina Santero, Adriana-G Meade, María Jesús Quintana, Gerardo Rodríguez-Grijalva, Anna Selva, Ivan Solà, Gerard Urrútia, Xavier Bonfill Cosp
Clinical Epidemiology.2023; Volume 15: 1069. CrossRef

8,159 View
213 Download
8 Web of Science
6 Crossref

A Phase II Trial of Docetaxel and Ifosfamide for Patients with Platinum-Resistant or Refractory Non-Small Cell Lung Cancer in a Salvage Setting: Gyeong-Won Lee, Jung-Hun Kang, Seok-Hyun Kim, Hea Yong Lee, Ho-Cheol Kim, Won-Sup Lee, Jong-Duk Lee, Young-Sil Hwang, Joung-Soon Jang, Jong-Seok Lee; Cancer Res Treat. 2004;36(5):287-292. Published online October 31, 2004; DOI: https://doi.org/10.4143/crt.2004.36.5.287

Abstract PDF PubReader ePub

Purpose

We conducted a phase II study of docetaxel and ifosfamide chemotherapy for patients with platinum-resistant or refractory non-small-cell lung cancer (NSCLC) to evaluate the response and toxicity profiles as a salvage treatment.

Materials and Methods

Between July 2000 and July 2004, 40 patients who had previously received platinum-based regimen as the first-line or second-line therapy were enrolled in this study. The treatment consisted of a docetaxel 75 mg/m² intravenous infusion on day 1 and intravenous ifosfamide 3 g/m² with Mesna® uroprotectione on day 1 through 3. This regimen was repeated every 3 weeks.

Results

One hundred thirty cycles of treatment were given, with a median of 3 cycles (range: 2~6 cycles). All the patients were evaluable for the response rate and toxicity profile. The major toxicity was myelosuppression. Grade 3~4 neutropenia occurred in 30 patients (75%) during treatment. Febrile neutropenia occurred in 16 patients (40%). Five of 40 patients (12.5%) had a partial response (95% confidence interval, 3.3~21.7%). The median time to disease progression was 2.65 months (range: 2.02~3.20 months), and the median survival was 5.24 months (range: 2.99~7.49 months).

Conclusion

Salvage chemotherapy with docetaxel and ifosfamide showed a low efficacy and a high proportion of severe neutropenia in patients with platinum-resistant or refractory advanced NSCLC.

Citations

Citations to this article as recorded by

The Safety and Efficacy of Second-line Single Docetaxel (75 mg/m2) Therapy in Advanced Non-Small Cell Lung Cancer Patients who were Previously Treated with Platinum-based Chemotherapy
Byoung Yong Shim, Chi Hong Kim, So Hyang Song, Meyung Im Ahn, Eun Jung Hong, Sung Whan Kim, Suzy Kim, Min Seop Jo, Deog Gon Cho, Kyu Do Cho, Jinyoung Yoo, Hoon-Kyo Kim
Cancer Research and Treatment.2005; 37(6): 339. CrossRef

9,455 View
52 Download
1 Crossref

First
Prev
Page of 1
Next
Last

Search